| 1 Pain on weight bearing (0‐100 mm VAS) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 1.1 1 to 4 weeks post‐injection |
1 |
55 |
Mean Difference (IV, Fixed, 95% CI) |
5.03 [‐4.94, 15.00] |
| 1.2 5 to 13 weeks post‐injection |
1 |
55 |
Mean Difference (IV, Fixed, 95% CI) |
‐15.64 [‐24.51, ‐6.77] |
| 1.3 14 to 26 weeks post‐injection |
1 |
55 |
Mean Difference (IV, Fixed, 95% CI) |
‐15.40 [‐25.91, ‐4.89] |
| 2 Pain at rest (0‐100 mm VAS) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 2.1 1 to 4 weeks post‐injection |
1 |
55 |
Mean Difference (IV, Fixed, 95% CI) |
3.53 [‐2.09, 9.15] |
| 2.2 5 to 13 weeks post‐injection |
1 |
55 |
Mean Difference (IV, Fixed, 95% CI) |
‐7.70 [‐13.50, ‐1.90] |
| 2.3 14 to 26 weeks post‐injection |
1 |
55 |
Mean Difference (IV, Fixed, 95% CI) |
‐2.90 [‐9.47, 3.67] |
| 3 Pain on walking (0‐100 mm VAS) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 3.1 1 to 4 weeks post‐injection |
1 |
55 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.40 [‐11.46, 10.66] |
| 3.2 5 to 13 weeks post‐injection |
1 |
55 |
Mean Difference (IV, Fixed, 95% CI) |
‐18.43 [‐29.19, ‐7.67] |
| 3.3 14 to 26 weeks post‐injection |
1 |
55 |
Mean Difference (IV, Fixed, 95% CI) |
‐14.90 [‐25.91, ‐3.89] |
| 4 Lequesne Index (0‐24) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 4.1 1 to 4 weeks post‐injection |
1 |
55 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.10 [‐0.91, 0.71] |
| 4.2 5 to 13 weeks post‐injection |
1 |
55 |
Mean Difference (IV, Fixed, 95% CI) |
‐1.40 [‐2.13, ‐0.67] |
| 4.3 14 to 26 weeks post‐injection |
1 |
55 |
Mean Difference (IV, Fixed, 95% CI) |
‐1.14 [‐2.16, ‐0.12] |
| 5 Flexion (active range in degrees) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 5.1 1 to 4 weeks post‐injection |
1 |
55 |
Mean Difference (IV, Fixed, 95% CI) |
2.16 [‐2.58, 6.90] |
| 5.2 5 to 13 weeks post‐injection |
1 |
55 |
Mean Difference (IV, Fixed, 95% CI) |
2.36 [‐1.82, 6.54] |
| 5.3 14 to 26 weeks post‐injection |
1 |
55 |
Mean Difference (IV, Fixed, 95% CI) |
5.0 [0.19, 9.81] |
| 6 Safety: total withdrawals overall |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 7 Safety: number of patients withdrawn due to increased pain |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 8 Safety: number of patients reporting musculoskeletal adverse events |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 9 Safety: number of patients reporting skin adverse events |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 10 Safety: number of patients reporting gastrointestinal adverse events |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 11 Safety: number of patients reporting general adverse events |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 12 Safety: number of patients reporting knee pain after injection |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
